Evidence map›Paper›PMID 41469148›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.

Julia Sheehan-Klenk, Hima Makala, Joon-Yong Chung, Woonghee Lee, Kwamena E Baidoo, Divya Nambiar, Nada Alani, Stephen M Hewitt, Yuki Ueda, Satoshi Omiya and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Julia Sheehan-KlenkMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Hima MakalaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Woonghee LeeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kwamena E BaidooMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Divya NambiarMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Nada AlaniLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and.
Stephen M HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and.
Yuki UedaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Satoshi OmiyaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Freddy E EscorciaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; freddy.escorcia@gmail.com.

Funding

Engineering HCC-selective PET agentZIABC011800 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ESCORCIA, FREDDY · 2018 to 2025
$10.6M
Intramural NIH HHS ZIA BC011800
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer-related mortality worldwide. Although HCC-selective diagnostics and treatments remain limited for late-stage disease, tumor-targeted radiopharmaceuticals offer a promising strategy to address this unmet need. Here, we identify tetraspanin-8 (TSPAN8) as a novel tumor-selective immuno-PET imaging target in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPositron-Emission TomographyTetraspaninsAnimalsCell Line, TumorHumansMiceRadiopharmaceuticalsTissue DistributionRadiopharmaceuticalsTetraspaninsTSPAN8 protein, humanhepatocellular carcinomaimmuno-PETmolecular imagingradiotheranosticsTSPAN8

Identifiers

PMID41469148
PMCPMC12955505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.